How much did Immunome achieve in EBIT for the current year?
In the current year, Immunome has achieved an EBIT of -252.45 M USD.
Immunome EBIT 2024
Immunome EBIT
-252.45 M USD
Ticker
IMNM
ISIN
US45257U1088
WKN
A2QD9D
In 2024, Immunome's EBIT was -252.45 M USD, a 778.77% increase from the -28.73 M USD EBIT recorded in the previous year.
The Immunome EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
Immunome Revenue, EBIT, Net Income US45257U1088 · A2QD9D
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Immunome, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immunome from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immunome’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Immunome. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Immunome’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Immunome’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immunome’s growth potential.
Immunome Revenue, EBIT and net profit per share
| Date | Immunome Revenue | Immunome EBIT | Immunome Net Income |
|---|---|---|---|
| 2029e | 251.59 M undefined | 0 undefined | 133.43 M undefined |
| 2028e | 170.84 M undefined | -93.33 M undefined | -6.99 M undefined |
| 2027e | 69.85 M undefined | -183.18 M undefined | -138.19 M undefined |
| 2026e | 19.72 M undefined | -226.29 M undefined | -197.17 M undefined |
| 2025e | 0 undefined | -196.76 M undefined | -184.22 M undefined |
| 2024e | 8.57 M undefined | -252.45 M undefined | -259.23 M undefined |
| 2023 | 14.02 M undefined | -28.73 M undefined | -106.81 M undefined |
| 2022 | 0 undefined | -36.9 M undefined | -37.52 M undefined |
| 2021 | 0 undefined | -25.2 M undefined | -24.71 M undefined |
| 2020 | 0 undefined | -12.26 M undefined | -17.84 M undefined |
| 2019 | 0 undefined | -10.35 M undefined | -10.44 M undefined |
| 2018 | 0 undefined | -7.74 M undefined | -7.85 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2018 | 0 USD | -7.74 M USD | -7.85 M USD |
| 2019 | 0 USD | -10.35 M USD | -10.44 M USD |
| 2020 | 0 USD | -12.26 M USD | -17.84 M USD |
| 2021 | 0 USD | -25.2 M USD | -24.71 M USD |
| 2022 | 0 USD | -36.9 M USD | -37.52 M USD |
| 2023 | 14.02 M USD | -28.73 M USD | -106.81 M USD |
| 2024e | 8.57 M USD | -252.45 M USD | -259.23 M USD |
| 2025e | 0 USD | -196.76 M USD | -184.22 M USD |
| 2026e | 19.72 M USD | -226.29 M USD | -197.17 M USD |
| 2027e | 69.85 M USD | -183.18 M USD | -138.19 M USD |
| 2028e | 170.84 M USD | -93.33 M USD | -6.99 M USD |
| 2029e | 251.59 M USD | 0 USD | 133.43 M USD |
Immunome stock margins US45257U1088 · A2QD9D
The Immunome margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunome. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunome.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Immunome's sales revenue. A higher gross margin percentage indicates that the Immunome retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Immunome's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Immunome's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immunome's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immunome. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immunome's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Immunome Margin History
| Immunome Gross margin | Immunome Profit margin | Immunome EBIT margin | Immunome Profit margin |
|---|---|---|---|
| 2029e | 0 % | 0 % | 53.03 % |
| 2028e | 0 % | -54.63 % | -4.09 % |
| 2027e | 0 % | -262.24 % | -197.84 % |
| 2026e | 0 % | -1,147.7 % | -1,000.01 % |
| 2025e | 0 % | 0 % | 0 % |
| 2024e | 0 % | -2,946.81 % | -3,025.87 % |
| 2023 | 0 % | -204.94 % | -761.92 % |
| 2022 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2018 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2023 | 0 % | -204.94 % | -761.92 % |
| 2024e | 0 % | -2,946.81 % | -3,025.87 % |
| 2025e | 0 % | 0 % | 0 % |
| 2026e | 0 % | -1,147.7 % | -1,000.01 % |
| 2027e | 0 % | -262.24 % | -197.84 % |
| 2028e | 0 % | -54.63 % | -4.09 % |
| 2029e | 0 % | 0 % | 53.03 % |
Immunome Aktienanalyse
What does Immunome do?
Immunome Inc was founded in 2020 and is based in Pennsylvania, USA. The company specializes in researching and developing therapeutic antibodies and vaccines. Its goal is to develop innovative drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The history of Immunome Inc began with the founding by a group of scientists and entrepreneurs who combined their expertise and experience in the field of immunology and biotechnology. Their goal was to build a company capable of conducting groundbreaking research and developing new therapies that offer improved chances of recovery. The business model is based on the discovery and development of monoclonal antibodies that have high specificity and effectiveness against specific target molecules. The strategy is to focus on new approaches to identify target molecules in order to develop drugs that specifically target the causes of diseases. Immunome Inc specializes in various areas: cancer, infectious diseases, and autoimmune diseases. Within these areas, the company focuses on identifying target molecules and developing monoclonal antibodies and vaccines that act specifically against these molecules. Products offered by Immunome Inc include monoclonal antibodies against various types of cancer such as breast cancer, prostate cancer, and lung cancer. These antibodies are currently being tested in clinical trials and show promising results. The company also offers a range of vaccines against various infectious diseases, including adaptable influenza vaccines and vaccines against the Ebola virus. In addition, Immunome Inc places great importance on the development of therapies for autoimmune diseases. This includes, for example, the discovery of autoantibodies that selectively balance the immune system and thus can control autoimmune diseases. In summary, Immunome Inc is an innovative biotech company specializing in the development and commercialization of monoclonal antibodies and vaccines against cancer, infectious diseases, and autoimmune diseases. Through its groundbreaking research, the company has the potential to save lives and contribute to the cure of diseases. Immunome ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Immunome's EBIT
Immunome's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Immunome's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Immunome's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Immunome’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Immunome stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Immunome.
How has the EBIT of Immunome developed in recent years?
The EBIT of Immunome has increased by 778.77% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Immunome?
The EBIT of Immunome is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Immunome pay?
Over the past 12 months, Immunome paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunome is expected to pay a dividend of 0 USD.
What is the dividend yield of Immunome?
The current dividend yield of Immunome is .
When does Immunome pay dividends?
Immunome pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immunome?
Immunome paid dividends every year for the past 0 years.
What is the dividend of Immunome?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immunome located?
Immunome is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immunome kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immunome from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.
When did Immunome pay the last dividend?
The last dividend was paid out on 11/9/2024.
What was the dividend of Immunome in the year 2023?
In the year 2023, Immunome distributed 0 USD as dividends.
In which currency does Immunome pay out the dividend?
The dividends of Immunome are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immunome
Our stock analysis for Immunome Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunome Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
